Elekta（EKTA.F）株式概要エレクタAB（publish）は医療技術企業で、がんや脳障害の治療のための臨床ソリューションの提供を世界中で行っている。 詳細EKTA.F ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長3/6過去の実績0/6財務の健全性3/6配当金3/6報酬当社が推定した公正価値より37.2%で取引されている 収益は年間34.81%増加すると予測されています リスク分析株式の流動性は非常に低い 多額の負債を抱えている 3.96%の配当は利益で十分にカバーされていない すべてのリスクチェックを見るEKTA.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$6.5054.6% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-40m21b2016201920222025202620282031Revenue SEK 21.4bEarnings SEK 2.9bAdvancedSet Fair ValueView all narrativesElekta AB (publ) 競合他社OmnicellSymbol: NasdaqGS:OMCLMarket cap: US$2.0bLeMaitre VascularSymbol: NasdaqGM:LMATMarket cap: US$2.3bNovoCureSymbol: NasdaqGS:NVCRMarket cap: US$2.1bAxogenSymbol: NasdaqCM:AXGNMarket cap: US$2.2b価格と性能株価の高値、安値、推移の概要Elekta過去の株価現在の株価SEK 6.5052週高値SEK 6.8352週安値SEK 4.48ベータ0.961ヶ月の変化4.84%3ヶ月変化6.56%1年変化18.98%3年間の変化-22.06%5年間の変化-53.24%IPOからの変化-50.00%最新ニュースお知らせ • May 19Elekta AB (publ) to Report Fiscal Year 2026 Final Results on Jul 03, 2026Elekta AB (publ) announced that they will report fiscal year 2026 final results at 9:00 AM, Central European Standard Time on Jul 03, 2026お知らせ • Mar 05+ 1 more updateElekta AB (publ) to Report Q2, 2027 Results on Nov 25, 2026Elekta AB (publ) announced that they will report Q2, 2027 results on Nov 25, 2026お知らせ • Feb 26Elekta AB (publ), Annual General Meeting, Sep 03, 2026Elekta AB (publ), Annual General Meeting, Sep 03, 2026.お知らせ • Jan 23Elekta AB Appoints Tomas Eliasson as Vice Chair of the Board, Effective January 23, 2026Elekta AB has established the role of Vice Chair of the Board and appointed Tomas Eliasson to this position, effective January 23, 2026. Tomas Eliasson has been a member of Elekta’s Board of Directors since 2023 and the Chair of its Audit Committee since 2024. He brings extensive experience from senior leadership and board roles in global industrial and technology-driven companies. His background includes deep expertise in finance, governance and strategy, supporting Elekta’s continued focus on long-term value creation.お知らせ • Jan 16Elekta Receives FDA 510(K) Clearance for Elekta Evo Linear AcceleratorElekta announced that its Elekta Evo CT-Linac has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This milestone makes the system available to radiation oncology professionals in the United States. When delivering radiation therapy, clinicians require high-quality images that allow them to identify tumors and organs-at-risk. Evo addresses this with Iris®? high-definition, AI-enhanced imaging, which allows physicians to see target areas and critical structures for every fraction with greater clarity. In Europe and other countries, Elekta Evo continues to gain traction, setting new benchmarks in radiation therapy as more clinics adopt its innovative treatment capabilities.お知らせ • Sep 04+ 1 more updateElekta AB (Publ) Elects Jan De Witte as DirectorElekta AB (publ) at its AGM held on September 4, 2025 approved to elect Jan De Witte, as Director for the period until the end of the next Annual General Meeting.最新情報をもっと見るRecent updatesお知らせ • May 19Elekta AB (publ) to Report Fiscal Year 2026 Final Results on Jul 03, 2026Elekta AB (publ) announced that they will report fiscal year 2026 final results at 9:00 AM, Central European Standard Time on Jul 03, 2026お知らせ • Mar 05+ 1 more updateElekta AB (publ) to Report Q2, 2027 Results on Nov 25, 2026Elekta AB (publ) announced that they will report Q2, 2027 results on Nov 25, 2026お知らせ • Feb 26Elekta AB (publ), Annual General Meeting, Sep 03, 2026Elekta AB (publ), Annual General Meeting, Sep 03, 2026.お知らせ • Jan 23Elekta AB Appoints Tomas Eliasson as Vice Chair of the Board, Effective January 23, 2026Elekta AB has established the role of Vice Chair of the Board and appointed Tomas Eliasson to this position, effective January 23, 2026. Tomas Eliasson has been a member of Elekta’s Board of Directors since 2023 and the Chair of its Audit Committee since 2024. He brings extensive experience from senior leadership and board roles in global industrial and technology-driven companies. His background includes deep expertise in finance, governance and strategy, supporting Elekta’s continued focus on long-term value creation.お知らせ • Jan 16Elekta Receives FDA 510(K) Clearance for Elekta Evo Linear AcceleratorElekta announced that its Elekta Evo CT-Linac has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This milestone makes the system available to radiation oncology professionals in the United States. When delivering radiation therapy, clinicians require high-quality images that allow them to identify tumors and organs-at-risk. Evo addresses this with Iris®? high-definition, AI-enhanced imaging, which allows physicians to see target areas and critical structures for every fraction with greater clarity. In Europe and other countries, Elekta Evo continues to gain traction, setting new benchmarks in radiation therapy as more clinics adopt its innovative treatment capabilities.お知らせ • Sep 04+ 1 more updateElekta AB (Publ) Elects Jan De Witte as DirectorElekta AB (publ) at its AGM held on September 4, 2025 approved to elect Jan De Witte, as Director for the period until the end of the next Annual General Meeting.お知らせ • Aug 28Elekta AB (publ) Provides Earnings Guidance for the Second Quarter 2025-2026 and Reiterates Earnings Guidance for the Year 2025-2026Elekta AB (publ) provided earnings guidance for the second quarter 2025-2026 and reiterated earnings guidance for the year 2025-2026. The company expects net sales for second quarter to be negatively impacted by a continued weak US development as well as a negative effect from last year's low order intake in China. However, The company expects sales in China to start to recover during the second half of 2025/26. Furthermore, company expect a continuous negative impact on earnings from FX at current exchange rates and from tariffs in second quarter. The company reiterates full year 2025-2026 outlook, where the company expects net sales in constant currency to grow year-over-year.お知らせ • May 29Elekta AB (publ), Annual General Meeting, Sep 04, 2025Elekta AB (publ), Annual General Meeting, Sep 04, 2025.お知らせ • May 28+ 1 more updateElekta AB (publ) Proposes Dividend for the Fiscal Year 2024/25The Board of Directors of Elekta AB (publ) proposed a dividend of SEK 2.40 (SEK 2.40) per share (paid in two installments) for 2024/25 amounting to SEK 917 million.お知らせ • May 19+ 1 more updateElekta AB (publ) to Report Q3, 2026 Results on Mar 05, 2026Elekta AB (publ) announced that they will report Q3, 2026 results on Mar 05, 2026お知らせ • May 05Elekta Announces Use of Its 1.5T Elekta Unity MR-LinacElekta announced that use of its 1.5T Elekta Unity MR-Linac can enable doctors to reduce the radiation dose to key structures responsible for erection among men being treated for prostate cancer. The preliminary results of the ERECT (EREctile Function Preservation for Prostate Cancer Radiation Therapy) trial were presented by University Medical Center Utrecht (UMC Utrecht, the Netherlands) clinicians at the 2025 European Society for Radiotherapy and Oncology (ESTRO) annual congress, May 2-6 in Vienna, Austria. The ERECT Trial is a sub-study of MOMENTUM, the MR-Linac Consortium's platform registry. It showed reduced incidence of erectile dysfunction (ED) and preserved erectile function up to 18 months using MR-guided radiotherapy (MRgRT) compared to conventional radiotherapy in patients with localized prostate cancer. In the study, researchers used Elekta Unity MR- Linac to treat 70 intermediate risk prostate cancer patients with a radiation dose of 36.25 Gy over five fractions. According to UMC Utrecht radiation oncologist and trial principal investor, Jochem van der Voort van Zyp, MD, PhD, Unity's pristine MR image quality not only enabled detailed visualization of the prostate, but also that of critical structures needed to achieve and maintain an erection. This anatomy includes the neurovascular bundle, internal pudendal arteries, corpora cavernosa and penile bulb. The endpoint of this preliminary analysis was the incidence of ED - as reported by patients - at six, 12- and 18-months post-treatment, compared to a control group that received the same dosage without neurovascular sparing. ED incidence was significantly lower in ERECT patients at all time points (six months: 6% vs. 21%, 12 months: 8.5% vs. 38%, 18 months: 16% vs. 36%). MRI is the gold standard for visualizing the prostate and surrounding structures in diagnostic radiology. Elekta Unity MR-Liac is the world's first and only device to combine a high-field MRI with a linear accelerator and enables clinicians to use MRI to guide radiation delivery to tumor targets and avoid surrounding structures. In addition, while treatment is ongoing, the system allows clinicians to non-invasively monitor the position of the target. If for example, if a prostate shifts due to motion of the bowels or bladder filling, the radiation treatment can be discontinued to avoid unnecessary radiation to surrounding normal tissues.お知らせ • Feb 27+ 1 more updateElekta AB (Publ) Announces Management ChangesElekta AB (publ) announced that Gustaf Salford, President and the Board of Directors, have decided that Gustaf will leave Elekta as of March 6, 2025. The Board of Directors has appointed Jonas Bolander, who has 23 years' experience at Elekta, as Acting President.お知らせ • Nov 27+ 2 more updatesElekta AB (publ) to Report Q2, 2026 Results on Nov 26, 2025Elekta AB (publ) announced that they will report Q2, 2026 results on Nov 26, 2025お知らせ • Nov 01Caroline Leksell Cooke Steps Down from Elekta AB's Board of DirectorsElekta AB announced that Caroline Leksell Cooke will step down from her role on the Board of Directors, effective November 1, 2024. This follows the earlier announcement that Caroline Leksell Cooke will assume the role of Senior Vice President and Head of Neuro Solutions, effective the same date, and in connection therewith leave her position as a board member.お知らせ • Sep 27Elekta AB Submits Elekta Evo to U.S. FDA for Premarket ApprovalElekta AB announced that its AI-powered adaptive CT-Linear Accelerator, Elekta Evo has been submitted and is now pending 510(k) premarket approval from the U.S. Food and Drug Administration (FDA) - this, less than a week after Evo received CE mark for sales and marketing in the European Union.お知らせ • Sep 06Elekta AB (Publ) Approves Dividend, Payable on September 12, 2024, and on March 12, 2025, RespectivelyElekta AB (publ) at its AGM held on September 5, 2024, approved dividend corresponding to SEK 2.40 per share and that the remaining profits are carried forward. The dividend is to be divided into two payments of SEK 1.20 per payment. The first record day is September 9, 2024. The second record day is March 7, 2025. The dividend is expected to be paid out on September 12, 2024, and on March 12, 2025, respectively.お知らせ • Jul 06Elekta AB (publ) to Report Q4, 2025 Results on May 28, 2025Elekta AB (publ) announced that they will report Q4, 2025 results on May 28, 2025お知らせ • Jun 06Elekta AB (publ) to Report Q3, 2025 Results on Feb 21, 2025Elekta AB (publ) announced that they will report Q3, 2025 results on Feb 21, 2025お知らせ • Mar 02Elekta AB (publ) Announces Resignation of Kelly Londy, Member of the BoardElekta AB announced that Kelly Londy, Member of the Board, will step down from her position and all board responsibilities, effective March 1, 2024. Ms. Londy has assumed a new senior executive role at another company, which will require her full attention. She has contributed significantly to Elekta’s Board and been greatly appreciated by her fellow board members. Elekta expresses its sincere gratitude to Ms. Londy for her dedicated service and wishes her continued success in her future role.お知らせ • Feb 29Elekta AB (publ) to Report Q2, 2025 Results on Nov 27, 2024Elekta AB (publ) announced that they will report Q2, 2025 results on Nov 27, 2024お知らせ • Nov 30+ 1 more updateElekta AB (publ) to Report Fiscal Year 2024 Final Results on Jul 05, 2024Elekta AB (publ) announced that they will report fiscal year 2024 final results on Jul 05, 2024お知らせ • Nov 01Elekta AB (publ) Announces Composition of Nomination CommitteeElekta AB (publ) announced that Annual General Meeting on August 24, 2023, the Chairman of the Board has convened the Nomination Committee for the 2024 Annual General Meeting by contacting the company's shareholders in terms of votes, in addition to the shareholder or shareholders represented by the Chairman himself. The procedure is described in detail in the notice to the 2020 Annual General Meeting. The Nomination Committee consists of: Laurent Leksell, in his capacity as Chairman of the Board of Elekta and representing his own and related parties' holdings; Thomas Wuolikainen, appointed by the Fourth Swedish National Pension Fund; Katarina Hammar, appointed by Nordea Funds; Patrik Jönsson, appointed by SEB Funds; Jesper Bergström, appointed by Handelsbanken Funds.お知らせ • Oct 24Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD).Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD) on October 23, 2023. The intention is to complete the transaction during the second quarter of Elekta’s fiscal year 2023/24.お知らせ • Oct 13Elekta AB (publ), Annual General Meeting, Sep 05, 2024Elekta AB (publ), Annual General Meeting, Sep 05, 2024.お知らせ • Aug 25+ 1 more updateElekta AB (Publ) Approves Dividend, Payable on 31 August, 2023 and 1 March, 2024, RespectivelyElekta AB (publ) announced that at its AGM held on 24 August 2023, the Meeting resolved on a dividend corresponding to SEK 2.40 per share and that the remaining profits are carried forward. The dividend is to be divided into two payments of SEK 1.20 per payment. The first record day is 28 August, 2023. The second record day is 27 February, 2024. The dividend is expected to be paid out on 31 August, 2023 and on 1 March, 2024 respectively.お知らせ • Jun 30Johan Malmquist Declines Re-Election as Director of Elekta AB (Publ)Elekta AB (publ) announced that 2023 Annual General Meeting to held on 24 August 2023, Johan Malmquist has declined re-election as director of the company.お知らせ • May 26+ 1 more updateElekta AB (publ) to Report Q3, 2024 Results on Feb 29, 2024Elekta AB (publ) announced that they will report Q3, 2024 results on Feb 29, 2024お知らせ • May 25+ 1 more updateElekta AB (publ) Provides Earnings Guidance for the Fiscal Year from 2022-2023 to 2024-2025Elekta AB (publ) provided earnings guidance for the fiscal year from 2022-2023 to 2024-2025. For the period, the company expects net sales CAGR of above 7%.お知らせ • May 13Elekta AB (Publ) Announces the Launch of the First Phase of Elekta ONEElekta AB (publ) is excited to announced the launch of the first phase of Elekta ONE, its most comprehensive and advanced software portfolio for oncology departments and clinics, including radiation therapy planning, comprehensive treatment management, and delivery. It brings all Elekta software products, solutions and services under one umbrella providing all users with one unified software experience. Previously, many cancer clinics have wrestled with stand-alone, closed systems, each with a different purpose. The result has been an unfavorable user experience and steep learning curve, adding pressure to an already strained resource: the clinical team. Elekta ONE aims to improve efficiency in the clinic by as much as 50%, eventually through smarter workflows, increased automation, and by learning from every patient treated. Its workflow-driven approach and deep integration between applications allows information to flow freely, giving clinicians a seamless user experience.お知らせ • Feb 14Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter.Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter on February 13, 2023. The first quarter of Elekta’s fiscal year 2023-2024.お知らせ • Nov 24Elekta AB (publ), Annual General Meeting, Aug 24, 2023Elekta AB (publ), Annual General Meeting, Aug 24, 2023.お知らせ • Jul 09+ 1 more updateElekta AB (publ) to Report Fiscal Year 2023 Results on May 25, 2023Elekta AB (publ) announced that they will report fiscal year 2023 results on May 25, 2023お知らせ • Nov 26+ 1 more updateElekta Appoints Gustaf Salford as CEOElekta announced that Gustaf Salford has been appointed to the role of CEO, effective immediately. He has been Acting CEO since early June 2020. Elekta's Board of Directors carried out an extensive search process, with the conclusion that Gustaf Salford fulfills all criteria that Elekta needs to continue to drive successful development. In addition to an MSc degree in Business Administration from the Stockholm School of Economics, Salford brings broad experience from different roles at Elekta and previously from senior management consulting, as well as intimate knowledge of the medical device industry.お知らせ • Nov 19Elekta Introduces Elekta Studio with Its Launch of the ImagingRingElekta introduced Elekta Studio with its launch of the ImagingRing, an advanced interventional CT system that revolves around the patient and enables clinicians to conduct the entire brachytherapy workflow - including applicator /needle insertion, imaging, planning and treatment delivery - without moving the patient from room to room. Elekta Studio was designed to radically simplify the 3D image-guided adaptive brachytherapy workflow and increase patient comfort. The ImagingRing is mobile, so it can be transported throughout the hospital to any desired location. A conventional CT, whether stationary or mobile, cannot offer real-time imaging nor the access to the patient as the ImagingRing does with its sleek design. With the ImagingRing, no time has to be spent moving the patient from the treatment table to the CT and back, so applicator displacement is avoided, increasing treatment accuracy and patient comfort. In addition, since the ImagingRing is at the heart of the Elekta Studio, system transport and waiting times for an imaging slot - such as for a traditional CT scan - are eliminated, thus accelerating the workflow.お知らせ • Sep 26Elekta Early Out in Securing MDR Certificates for Its Linac PortfolioElekta announced it has received the EU Medical Device Regulation (EU MDR) certificate for its linear accelerator (linac) portfolio. More than 4,000 Elekta linacs are currently clinical around the world, treating patients with a wide variety of cancers. The MDR certificate applies to the following products, including their components and accessories: Versa HD™; Elekta Synergy; Elekta Infinity. The EU MDR, ratified in May 2017, will become effective in May 2021, followed by a transition period until May 2024. Its purpose is to ensure that medical devices are introduced to and sold on the market within a robust, transparent and sustainable regulatory framework. Maurits Wolleswinkel, President Linac Solutions at Elekta, adds: "As a leading medical device company, we're proud that Elekta is among the first to guarantee that its customers will be able to continue offering their patients advanced cancer treatment without interruption. More importantly, it supports Elekta's promise to make quality radiation therapy accessible to all, especially during the Covid-19 pandemic." Elekta will continue its certification program to ensure that its advanced precision radiation medicine portfolio will be fully compliant during the MDR transition period.お知らせ • Aug 26Elekta AB (publ) to Report Fiscal Year 2021 Results on May 27, 2021Elekta AB (publ) announced that they will report fiscal year 2021 results at 5:39 AM, GMT Standard Time on May 27, 2021株主還元EKTA.FUS Medical EquipmentUS 市場7D7.3%4.4%1.0%1Y19.0%-17.9%28.7%株主還元を見る業界別リターン: EKTA.F過去 1 年間で-17.9 % の収益を上げたUS Medical Equipment業界を上回りました。リターン対市場: EKTA.Fは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is EKTA.F's price volatile compared to industry and market?EKTA.F volatilityEKTA.F Average Weekly Movementn/aMedical Equipment Industry Average Movement8.7%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: EKTA.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のEKTA.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト19724,438Jakob Just-Bomholtwww.elekta.comElekta AB (publish)は医療技術会社で、がんおよび脳疾患の治療のための臨床ソリューションの提供を世界中で行っている。同社は、リアルタイムMR可視化用Elekta Unity、脳転移ソリューションElekta Versa HD、リニアックElekta Harmony、単純から複雑な放射線治療を必要とする様々な患者の治療用Elekta Infinity、品質保証、治療および動作管理ソリューションなどの放射線治療製品を提供している。また、定位放射線手術製品として、Elekta Esprit、個別化放射線治療用Leksell Gamma Knife Icon、放射線外科医用ツールLeksell Gamma Knife Perfexion、治療計画・管理ソフトウェアLeksell GammaPlanを提供している。さらに、同社は複数のエレクタソリューションのソフトウェアスイートであるElekta ONEを提供している。さらに、画像ガイド下ブラキセラピーソリューション「Elekta Studio」、モバイルCTスキャナー「ImagingRing」、反復作業を容易にするスマートツール「Oncentra Brachy」、電子ブラキセラピーシステム「Elekta Xoft Axxent」、子宮頸がん患者用アプリケーター「Elekta Geneva」、ワークフローのすべてのステップを正確に実行できるアフターローダー「Elekta Flexitron」、腫瘍医が局所進行子宮頸がんを治療できるアプリケーター「Venezia」などのブラキセラピー製品を提供している。さらに、同社は頭蓋内神経外科手術用のLeksell Vantage Stereotactic Systemなどの神経外科製品を提供している。さらに、個別化がん治療のためのElekta Kaikuや動物用放射線治療ソリューションも提供している。同社は1972年に設立され、スウェーデンのストックホルムに本社を置いている。もっと見るElekta AB (publ) 基礎のまとめElekta の収益と売上を時価総額と比較するとどうか。EKTA.F 基礎統計学時価総額US$2.47b収益（TTM）-US$4.27m売上高(TTM)US$1.83b1.4xP/Sレシオ-578.9xPER（株価収益率EKTA.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計EKTA.F 損益計算書（TTM）収益SEK 17.11b売上原価SEK 10.52b売上総利益SEK 6.59bその他の費用SEK 6.63b収益-SEK 40.00m直近の収益報告Jan 31, 2026次回決算日May 28, 2026一株当たり利益（EPS）-0.10グロス・マージン38.51%純利益率-0.23%有利子負債／自己資本比率78.3%EKTA.F の長期的なパフォーマンスは？過去の実績と比較を見る配当金4.0%現在の配当利回り-2,293%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 17:53終値2026/05/20 00:00収益2026/01/31年間収益2025/04/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Elekta AB (publ) 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。30 アナリスト機関null nullABG Sundal CollierSally TaylorBarclaysHassan Al-WakeelBarclays27 その他のアナリストを表示
お知らせ • May 19Elekta AB (publ) to Report Fiscal Year 2026 Final Results on Jul 03, 2026Elekta AB (publ) announced that they will report fiscal year 2026 final results at 9:00 AM, Central European Standard Time on Jul 03, 2026
お知らせ • Mar 05+ 1 more updateElekta AB (publ) to Report Q2, 2027 Results on Nov 25, 2026Elekta AB (publ) announced that they will report Q2, 2027 results on Nov 25, 2026
お知らせ • Feb 26Elekta AB (publ), Annual General Meeting, Sep 03, 2026Elekta AB (publ), Annual General Meeting, Sep 03, 2026.
お知らせ • Jan 23Elekta AB Appoints Tomas Eliasson as Vice Chair of the Board, Effective January 23, 2026Elekta AB has established the role of Vice Chair of the Board and appointed Tomas Eliasson to this position, effective January 23, 2026. Tomas Eliasson has been a member of Elekta’s Board of Directors since 2023 and the Chair of its Audit Committee since 2024. He brings extensive experience from senior leadership and board roles in global industrial and technology-driven companies. His background includes deep expertise in finance, governance and strategy, supporting Elekta’s continued focus on long-term value creation.
お知らせ • Jan 16Elekta Receives FDA 510(K) Clearance for Elekta Evo Linear AcceleratorElekta announced that its Elekta Evo CT-Linac has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This milestone makes the system available to radiation oncology professionals in the United States. When delivering radiation therapy, clinicians require high-quality images that allow them to identify tumors and organs-at-risk. Evo addresses this with Iris®? high-definition, AI-enhanced imaging, which allows physicians to see target areas and critical structures for every fraction with greater clarity. In Europe and other countries, Elekta Evo continues to gain traction, setting new benchmarks in radiation therapy as more clinics adopt its innovative treatment capabilities.
お知らせ • Sep 04+ 1 more updateElekta AB (Publ) Elects Jan De Witte as DirectorElekta AB (publ) at its AGM held on September 4, 2025 approved to elect Jan De Witte, as Director for the period until the end of the next Annual General Meeting.
お知らせ • May 19Elekta AB (publ) to Report Fiscal Year 2026 Final Results on Jul 03, 2026Elekta AB (publ) announced that they will report fiscal year 2026 final results at 9:00 AM, Central European Standard Time on Jul 03, 2026
お知らせ • Mar 05+ 1 more updateElekta AB (publ) to Report Q2, 2027 Results on Nov 25, 2026Elekta AB (publ) announced that they will report Q2, 2027 results on Nov 25, 2026
お知らせ • Feb 26Elekta AB (publ), Annual General Meeting, Sep 03, 2026Elekta AB (publ), Annual General Meeting, Sep 03, 2026.
お知らせ • Jan 23Elekta AB Appoints Tomas Eliasson as Vice Chair of the Board, Effective January 23, 2026Elekta AB has established the role of Vice Chair of the Board and appointed Tomas Eliasson to this position, effective January 23, 2026. Tomas Eliasson has been a member of Elekta’s Board of Directors since 2023 and the Chair of its Audit Committee since 2024. He brings extensive experience from senior leadership and board roles in global industrial and technology-driven companies. His background includes deep expertise in finance, governance and strategy, supporting Elekta’s continued focus on long-term value creation.
お知らせ • Jan 16Elekta Receives FDA 510(K) Clearance for Elekta Evo Linear AcceleratorElekta announced that its Elekta Evo CT-Linac has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This milestone makes the system available to radiation oncology professionals in the United States. When delivering radiation therapy, clinicians require high-quality images that allow them to identify tumors and organs-at-risk. Evo addresses this with Iris®? high-definition, AI-enhanced imaging, which allows physicians to see target areas and critical structures for every fraction with greater clarity. In Europe and other countries, Elekta Evo continues to gain traction, setting new benchmarks in radiation therapy as more clinics adopt its innovative treatment capabilities.
お知らせ • Sep 04+ 1 more updateElekta AB (Publ) Elects Jan De Witte as DirectorElekta AB (publ) at its AGM held on September 4, 2025 approved to elect Jan De Witte, as Director for the period until the end of the next Annual General Meeting.
お知らせ • Aug 28Elekta AB (publ) Provides Earnings Guidance for the Second Quarter 2025-2026 and Reiterates Earnings Guidance for the Year 2025-2026Elekta AB (publ) provided earnings guidance for the second quarter 2025-2026 and reiterated earnings guidance for the year 2025-2026. The company expects net sales for second quarter to be negatively impacted by a continued weak US development as well as a negative effect from last year's low order intake in China. However, The company expects sales in China to start to recover during the second half of 2025/26. Furthermore, company expect a continuous negative impact on earnings from FX at current exchange rates and from tariffs in second quarter. The company reiterates full year 2025-2026 outlook, where the company expects net sales in constant currency to grow year-over-year.
お知らせ • May 29Elekta AB (publ), Annual General Meeting, Sep 04, 2025Elekta AB (publ), Annual General Meeting, Sep 04, 2025.
お知らせ • May 28+ 1 more updateElekta AB (publ) Proposes Dividend for the Fiscal Year 2024/25The Board of Directors of Elekta AB (publ) proposed a dividend of SEK 2.40 (SEK 2.40) per share (paid in two installments) for 2024/25 amounting to SEK 917 million.
お知らせ • May 19+ 1 more updateElekta AB (publ) to Report Q3, 2026 Results on Mar 05, 2026Elekta AB (publ) announced that they will report Q3, 2026 results on Mar 05, 2026
お知らせ • May 05Elekta Announces Use of Its 1.5T Elekta Unity MR-LinacElekta announced that use of its 1.5T Elekta Unity MR-Linac can enable doctors to reduce the radiation dose to key structures responsible for erection among men being treated for prostate cancer. The preliminary results of the ERECT (EREctile Function Preservation for Prostate Cancer Radiation Therapy) trial were presented by University Medical Center Utrecht (UMC Utrecht, the Netherlands) clinicians at the 2025 European Society for Radiotherapy and Oncology (ESTRO) annual congress, May 2-6 in Vienna, Austria. The ERECT Trial is a sub-study of MOMENTUM, the MR-Linac Consortium's platform registry. It showed reduced incidence of erectile dysfunction (ED) and preserved erectile function up to 18 months using MR-guided radiotherapy (MRgRT) compared to conventional radiotherapy in patients with localized prostate cancer. In the study, researchers used Elekta Unity MR- Linac to treat 70 intermediate risk prostate cancer patients with a radiation dose of 36.25 Gy over five fractions. According to UMC Utrecht radiation oncologist and trial principal investor, Jochem van der Voort van Zyp, MD, PhD, Unity's pristine MR image quality not only enabled detailed visualization of the prostate, but also that of critical structures needed to achieve and maintain an erection. This anatomy includes the neurovascular bundle, internal pudendal arteries, corpora cavernosa and penile bulb. The endpoint of this preliminary analysis was the incidence of ED - as reported by patients - at six, 12- and 18-months post-treatment, compared to a control group that received the same dosage without neurovascular sparing. ED incidence was significantly lower in ERECT patients at all time points (six months: 6% vs. 21%, 12 months: 8.5% vs. 38%, 18 months: 16% vs. 36%). MRI is the gold standard for visualizing the prostate and surrounding structures in diagnostic radiology. Elekta Unity MR-Liac is the world's first and only device to combine a high-field MRI with a linear accelerator and enables clinicians to use MRI to guide radiation delivery to tumor targets and avoid surrounding structures. In addition, while treatment is ongoing, the system allows clinicians to non-invasively monitor the position of the target. If for example, if a prostate shifts due to motion of the bowels or bladder filling, the radiation treatment can be discontinued to avoid unnecessary radiation to surrounding normal tissues.
お知らせ • Feb 27+ 1 more updateElekta AB (Publ) Announces Management ChangesElekta AB (publ) announced that Gustaf Salford, President and the Board of Directors, have decided that Gustaf will leave Elekta as of March 6, 2025. The Board of Directors has appointed Jonas Bolander, who has 23 years' experience at Elekta, as Acting President.
お知らせ • Nov 27+ 2 more updatesElekta AB (publ) to Report Q2, 2026 Results on Nov 26, 2025Elekta AB (publ) announced that they will report Q2, 2026 results on Nov 26, 2025
お知らせ • Nov 01Caroline Leksell Cooke Steps Down from Elekta AB's Board of DirectorsElekta AB announced that Caroline Leksell Cooke will step down from her role on the Board of Directors, effective November 1, 2024. This follows the earlier announcement that Caroline Leksell Cooke will assume the role of Senior Vice President and Head of Neuro Solutions, effective the same date, and in connection therewith leave her position as a board member.
お知らせ • Sep 27Elekta AB Submits Elekta Evo to U.S. FDA for Premarket ApprovalElekta AB announced that its AI-powered adaptive CT-Linear Accelerator, Elekta Evo has been submitted and is now pending 510(k) premarket approval from the U.S. Food and Drug Administration (FDA) - this, less than a week after Evo received CE mark for sales and marketing in the European Union.
お知らせ • Sep 06Elekta AB (Publ) Approves Dividend, Payable on September 12, 2024, and on March 12, 2025, RespectivelyElekta AB (publ) at its AGM held on September 5, 2024, approved dividend corresponding to SEK 2.40 per share and that the remaining profits are carried forward. The dividend is to be divided into two payments of SEK 1.20 per payment. The first record day is September 9, 2024. The second record day is March 7, 2025. The dividend is expected to be paid out on September 12, 2024, and on March 12, 2025, respectively.
お知らせ • Jul 06Elekta AB (publ) to Report Q4, 2025 Results on May 28, 2025Elekta AB (publ) announced that they will report Q4, 2025 results on May 28, 2025
お知らせ • Jun 06Elekta AB (publ) to Report Q3, 2025 Results on Feb 21, 2025Elekta AB (publ) announced that they will report Q3, 2025 results on Feb 21, 2025
お知らせ • Mar 02Elekta AB (publ) Announces Resignation of Kelly Londy, Member of the BoardElekta AB announced that Kelly Londy, Member of the Board, will step down from her position and all board responsibilities, effective March 1, 2024. Ms. Londy has assumed a new senior executive role at another company, which will require her full attention. She has contributed significantly to Elekta’s Board and been greatly appreciated by her fellow board members. Elekta expresses its sincere gratitude to Ms. Londy for her dedicated service and wishes her continued success in her future role.
お知らせ • Feb 29Elekta AB (publ) to Report Q2, 2025 Results on Nov 27, 2024Elekta AB (publ) announced that they will report Q2, 2025 results on Nov 27, 2024
お知らせ • Nov 30+ 1 more updateElekta AB (publ) to Report Fiscal Year 2024 Final Results on Jul 05, 2024Elekta AB (publ) announced that they will report fiscal year 2024 final results on Jul 05, 2024
お知らせ • Nov 01Elekta AB (publ) Announces Composition of Nomination CommitteeElekta AB (publ) announced that Annual General Meeting on August 24, 2023, the Chairman of the Board has convened the Nomination Committee for the 2024 Annual General Meeting by contacting the company's shareholders in terms of votes, in addition to the shareholder or shareholders represented by the Chairman himself. The procedure is described in detail in the notice to the 2020 Annual General Meeting. The Nomination Committee consists of: Laurent Leksell, in his capacity as Chairman of the Board of Elekta and representing his own and related parties' holdings; Thomas Wuolikainen, appointed by the Fourth Swedish National Pension Fund; Katarina Hammar, appointed by Nordea Funds; Patrik Jönsson, appointed by SEB Funds; Jesper Bergström, appointed by Handelsbanken Funds.
お知らせ • Oct 24Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD).Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD) on October 23, 2023. The intention is to complete the transaction during the second quarter of Elekta’s fiscal year 2023/24.
お知らせ • Oct 13Elekta AB (publ), Annual General Meeting, Sep 05, 2024Elekta AB (publ), Annual General Meeting, Sep 05, 2024.
お知らせ • Aug 25+ 1 more updateElekta AB (Publ) Approves Dividend, Payable on 31 August, 2023 and 1 March, 2024, RespectivelyElekta AB (publ) announced that at its AGM held on 24 August 2023, the Meeting resolved on a dividend corresponding to SEK 2.40 per share and that the remaining profits are carried forward. The dividend is to be divided into two payments of SEK 1.20 per payment. The first record day is 28 August, 2023. The second record day is 27 February, 2024. The dividend is expected to be paid out on 31 August, 2023 and on 1 March, 2024 respectively.
お知らせ • Jun 30Johan Malmquist Declines Re-Election as Director of Elekta AB (Publ)Elekta AB (publ) announced that 2023 Annual General Meeting to held on 24 August 2023, Johan Malmquist has declined re-election as director of the company.
お知らせ • May 26+ 1 more updateElekta AB (publ) to Report Q3, 2024 Results on Feb 29, 2024Elekta AB (publ) announced that they will report Q3, 2024 results on Feb 29, 2024
お知らせ • May 25+ 1 more updateElekta AB (publ) Provides Earnings Guidance for the Fiscal Year from 2022-2023 to 2024-2025Elekta AB (publ) provided earnings guidance for the fiscal year from 2022-2023 to 2024-2025. For the period, the company expects net sales CAGR of above 7%.
お知らせ • May 13Elekta AB (Publ) Announces the Launch of the First Phase of Elekta ONEElekta AB (publ) is excited to announced the launch of the first phase of Elekta ONE, its most comprehensive and advanced software portfolio for oncology departments and clinics, including radiation therapy planning, comprehensive treatment management, and delivery. It brings all Elekta software products, solutions and services under one umbrella providing all users with one unified software experience. Previously, many cancer clinics have wrestled with stand-alone, closed systems, each with a different purpose. The result has been an unfavorable user experience and steep learning curve, adding pressure to an already strained resource: the clinical team. Elekta ONE aims to improve efficiency in the clinic by as much as 50%, eventually through smarter workflows, increased automation, and by learning from every patient treated. Its workflow-driven approach and deep integration between applications allows information to flow freely, giving clinicians a seamless user experience.
お知らせ • Feb 14Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter.Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter on February 13, 2023. The first quarter of Elekta’s fiscal year 2023-2024.
お知らせ • Nov 24Elekta AB (publ), Annual General Meeting, Aug 24, 2023Elekta AB (publ), Annual General Meeting, Aug 24, 2023.
お知らせ • Jul 09+ 1 more updateElekta AB (publ) to Report Fiscal Year 2023 Results on May 25, 2023Elekta AB (publ) announced that they will report fiscal year 2023 results on May 25, 2023
お知らせ • Nov 26+ 1 more updateElekta Appoints Gustaf Salford as CEOElekta announced that Gustaf Salford has been appointed to the role of CEO, effective immediately. He has been Acting CEO since early June 2020. Elekta's Board of Directors carried out an extensive search process, with the conclusion that Gustaf Salford fulfills all criteria that Elekta needs to continue to drive successful development. In addition to an MSc degree in Business Administration from the Stockholm School of Economics, Salford brings broad experience from different roles at Elekta and previously from senior management consulting, as well as intimate knowledge of the medical device industry.
お知らせ • Nov 19Elekta Introduces Elekta Studio with Its Launch of the ImagingRingElekta introduced Elekta Studio with its launch of the ImagingRing, an advanced interventional CT system that revolves around the patient and enables clinicians to conduct the entire brachytherapy workflow - including applicator /needle insertion, imaging, planning and treatment delivery - without moving the patient from room to room. Elekta Studio was designed to radically simplify the 3D image-guided adaptive brachytherapy workflow and increase patient comfort. The ImagingRing is mobile, so it can be transported throughout the hospital to any desired location. A conventional CT, whether stationary or mobile, cannot offer real-time imaging nor the access to the patient as the ImagingRing does with its sleek design. With the ImagingRing, no time has to be spent moving the patient from the treatment table to the CT and back, so applicator displacement is avoided, increasing treatment accuracy and patient comfort. In addition, since the ImagingRing is at the heart of the Elekta Studio, system transport and waiting times for an imaging slot - such as for a traditional CT scan - are eliminated, thus accelerating the workflow.
お知らせ • Sep 26Elekta Early Out in Securing MDR Certificates for Its Linac PortfolioElekta announced it has received the EU Medical Device Regulation (EU MDR) certificate for its linear accelerator (linac) portfolio. More than 4,000 Elekta linacs are currently clinical around the world, treating patients with a wide variety of cancers. The MDR certificate applies to the following products, including their components and accessories: Versa HD™; Elekta Synergy; Elekta Infinity. The EU MDR, ratified in May 2017, will become effective in May 2021, followed by a transition period until May 2024. Its purpose is to ensure that medical devices are introduced to and sold on the market within a robust, transparent and sustainable regulatory framework. Maurits Wolleswinkel, President Linac Solutions at Elekta, adds: "As a leading medical device company, we're proud that Elekta is among the first to guarantee that its customers will be able to continue offering their patients advanced cancer treatment without interruption. More importantly, it supports Elekta's promise to make quality radiation therapy accessible to all, especially during the Covid-19 pandemic." Elekta will continue its certification program to ensure that its advanced precision radiation medicine portfolio will be fully compliant during the MDR transition period.
お知らせ • Aug 26Elekta AB (publ) to Report Fiscal Year 2021 Results on May 27, 2021Elekta AB (publ) announced that they will report fiscal year 2021 results at 5:39 AM, GMT Standard Time on May 27, 2021
